A federal appeals court has issued a ruling that prohibits the distribution of mifepristone, a medication commonly used for early abortion, through the mail. This decision represents a significant shift in abortion policy in the United States, occurring in the wake of the Supreme Court's overturning of Roe v. Wade. The unanimous ruling was delivered by the 5th U.S. Circuit Court of Appeals, based in New Orleans, and has implications for access to abortion services across the country. The court's decision is expected to impact how healthcare providers prescribe and dispense this medication.
Related Articles
Don't miss out on breaking stories and in-depth articles.